FDA
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase Deficiency Program
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) PT Lowered to $60 at H.C. Wainwright
-
-
-
-
-
-
-
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
-
-
-
-
-
-
-
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
-
-
-
-
-
-
-
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
-
-
-
-
-
-
-
Devonian Health Group Announces the Appointment of New Board Members and Grant of Stock Options
-
-
-
-
-
-
-
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

